Gosebruch Henry O
SEC CIK 1659625 · EDGAR
BoughtSold
Most active insiders at ANIP, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Lalwani Nikhil | Pres, CEO, Dir | — | $5.05M |
| 2 | Walsh Patrick D | Dir | — | $2.32M |
| 3 | CAREY STEPHEN P. | SVP, CFO | — | $1.78M |
| 4 | Mutz Christopher | HEAD OF RARE DISEASE | — | $1.64M |
| 5 | Gassert Chad | SVP - CORP. DEV, STRATEGY | — | $1.31M |
| 6 | Davis Krista | SVP, Chief HR Off | — | $918.6K |
| 7 | Gutwerg Ori | SVP, GENERICS | — | $621.4K |
| 8 | Cook Meredith | SVP, GC, SEC | — | $453.9K |
| 9 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | — | $393.8K |
| 10 | HAUGHEY THOMAS | Dir | — | $161.8K |
| 16 | Gosebruch Henry O | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-27 16:21 | 2026-08-19 | ANIP | ANI PHARMACEUTICALS INC | Gosebruch Henry O | Dir | A - Grant | $0.00 | +6,662 | 6,662 | New | $0 | |
| D | 2024-02-16 | 2024-02-14 | NMRA | Neumora Therapeutics, Inc. | Gosebruch Henry O | Pres, CEO, Dir | A - Grant | $0.00 | +80.0K | 462.3K | +21% | $0 |
| I | 2023-09-19 | 2023-09-19 | NMRA | Neumora Therapeutics, Inc. | Gosebruch Henry O | Pres, CEO, Dir | P - Purchase | $12.62 | +15.0K | 15.0K | New | +$189.3K |
| DA | 2022-05-20 | 2022-05-16 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | S - Sale+OE | $155.00 | -84.0K | 41.6K | -67% | -$13.01M |
| DA | 2022-05-20 | 2022-05-16 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | M - OptEx | $54.86 | +84.0K | 125.6K | +202% | +$4.61M |
| MAI | 2022-05-20 | 2022-03-01 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | S - Sale | $147.29 | -25.0K | 53.6K | -32% | -$3.68M |
| D | 2022-05-18 | 2022-05-16 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | M - OptEx | $54.86 | +84.0K | 100.6K | +505% | +$4.61M |
| D | 2022-05-18 | 2022-05-16 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | S - Sale+OE | $155.00 | -84.0K | 16.6K | -83% | -$13.01M |
| M | 2022-03-02 | 2022-03-01 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | S - Sale | $147.29 | -25.0K | 16.6K | -60% | -$3.68M |
| M | 2022-03-01 | 2022-03-01 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | S - Sale | $148.26 | -15.0K | 41.6K | -26% | -$2.22M |
| 2022-03-01 | 2022-02-25 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | F - Tax | $149.54 | -30.2K | 56.6K | -35% | -$4.51M | |
| DM | 2022-02-22 | 2022-02-17 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | A - Grant | $0.00 | +68.1K | 86.8K | +364% | $0 |
| I | 2021-09-10 | 2021-09-07 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | G - Gift | $0.00 | +30.0K | 78.5K | +62% | $0 |
| 2021-09-10 | 2021-09-07 | ABBV | AbbVie | Gosebruch Henry O | EVP, Chief Strategy Off | G - Gift | $0.00 | -30.0K | 18.7K | -62% | $0 |
Purchase Sale Sale after option exercise All abbreviations